Diffuse Intrinsic Pontine Glioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major diffuse intrinsic pontine glioma markets reached a value of US$ 3.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.47% during 2024-2034.
The diffuse intrinsic pontine glioma market has been comprehensively analyzed in IMARC's new report titled "Diffuse Intrinsic Pontine Glioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diffuse intrinsic pontine glioma (DIPG) refers to a rare and highly aggressive brain tumor that primarily affects children, generally between the ages of 5 and 10. It arises in the pons, a crucial area of the brainstem responsible for vital functions like breathing, swallowing, and heartbeat regulation. DIPG is characterized by its diffuse and infiltrative nature, making surgical removal nearly impossible. The symptoms of the ailment often emerge rapidly as the tumor grows amidst delicate brain structures. Common signs include difficulty controlling eye movements, coordination problems, weakness, and trouble speaking or swallowing. As the tumor presses on the brainstem, it can lead to severe neurological deficits and impact the overall quality of life. Diagnosing DIPG typically involves magnetic resonance imaging (MRI) scans, which reveal the presence of a diffuse and often infiltrative tumor in the pons. A healthcare provider might also recommend a biopsy to confirm the diagnosis and analyze the tumor's characteristics more closely.
The increasing prevalence of somatic mutations in crucial genes, particularly those encoding histone proteins, leading to uncontrolled cell division and tumor formation in the brain is primarily driving the diffuse intrinsic pontine glioma market. In addition to this, the inflating utilization of advanced therapeutic approaches, including targeted radiation therapies, experimental drug regimens, and innovative surgical techniques, aimed at managing the condition and curbing its progression, is creating a positive outlook for the market. Moreover, the widespread adoption of supportive care measures, encompassing pain management, physical therapy, and cognitive support to enhance the quality of individuals suffering from the illness is further bolstering the market growth. Apart from this, the rising usage of convection-enhanced delivery (CED) methods that allow for direct administration of therapeutics into the tumor site, circumventing the blood-brain barrier, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of immunotherapies, which aim to modulate the immune system to recognize and attack cancer cells, is also augmenting the market growth. Furthermore, ongoing advancements in research and development, particularly in the field of gene editing techniques like CRISPR to target the genetic aberrations responsible for the disease, are expected to drive the diffuse intrinsic pontine glioma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the diffuse intrinsic pontine glioma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diffuse intrinsic pontine glioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diffuse intrinsic pontine glioma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the diffuse intrinsic pontine glioma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the diffuse intrinsic pontine glioma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current diffuse intrinsic pontine glioma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the diffuse intrinsic pontine glioma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the diffuse intrinsic pontine glioma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the diffuse intrinsic pontine glioma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of diffuse intrinsic pontine glioma across the seven major markets?
What is the number of prevalent cases (2018-2034) of diffuse intrinsic pontine glioma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of diffuse intrinsic pontine glioma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with diffuse intrinsic pontine glioma across the seven major markets?
What is the size of the diffuse intrinsic pontine glioma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of diffuse intrinsic pontine glioma?
What will be the growth rate of patients across the seven major markets?
Diffuse Intrinsic Pontine Glioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for diffuse intrinsic pontine glioma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diffuse intrinsic pontine glioma market?
What are the key regulatory events related to the diffuse intrinsic pontine glioma market?
What is the structure of clinical trial landscape by status related to the diffuse intrinsic pontine glioma market?
What is the structure of clinical trial landscape by phase related to the diffuse intrinsic pontine glioma market?
What is the structure of clinical trial landscape by route of administration related to the diffuse intrinsic pontine glioma market?
The diffuse intrinsic pontine glioma market has been comprehensively analyzed in IMARC's new report titled "Diffuse Intrinsic Pontine Glioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diffuse intrinsic pontine glioma (DIPG) refers to a rare and highly aggressive brain tumor that primarily affects children, generally between the ages of 5 and 10. It arises in the pons, a crucial area of the brainstem responsible for vital functions like breathing, swallowing, and heartbeat regulation. DIPG is characterized by its diffuse and infiltrative nature, making surgical removal nearly impossible. The symptoms of the ailment often emerge rapidly as the tumor grows amidst delicate brain structures. Common signs include difficulty controlling eye movements, coordination problems, weakness, and trouble speaking or swallowing. As the tumor presses on the brainstem, it can lead to severe neurological deficits and impact the overall quality of life. Diagnosing DIPG typically involves magnetic resonance imaging (MRI) scans, which reveal the presence of a diffuse and often infiltrative tumor in the pons. A healthcare provider might also recommend a biopsy to confirm the diagnosis and analyze the tumor's characteristics more closely.
The increasing prevalence of somatic mutations in crucial genes, particularly those encoding histone proteins, leading to uncontrolled cell division and tumor formation in the brain is primarily driving the diffuse intrinsic pontine glioma market. In addition to this, the inflating utilization of advanced therapeutic approaches, including targeted radiation therapies, experimental drug regimens, and innovative surgical techniques, aimed at managing the condition and curbing its progression, is creating a positive outlook for the market. Moreover, the widespread adoption of supportive care measures, encompassing pain management, physical therapy, and cognitive support to enhance the quality of individuals suffering from the illness is further bolstering the market growth. Apart from this, the rising usage of convection-enhanced delivery (CED) methods that allow for direct administration of therapeutics into the tumor site, circumventing the blood-brain barrier, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of immunotherapies, which aim to modulate the immune system to recognize and attack cancer cells, is also augmenting the market growth. Furthermore, ongoing advancements in research and development, particularly in the field of gene editing techniques like CRISPR to target the genetic aberrations responsible for the disease, are expected to drive the diffuse intrinsic pontine glioma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the diffuse intrinsic pontine glioma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diffuse intrinsic pontine glioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diffuse intrinsic pontine glioma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the diffuse intrinsic pontine glioma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the diffuse intrinsic pontine glioma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current diffuse intrinsic pontine glioma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the diffuse intrinsic pontine glioma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the diffuse intrinsic pontine glioma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the diffuse intrinsic pontine glioma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of diffuse intrinsic pontine glioma across the seven major markets?
What is the number of prevalent cases (2018-2034) of diffuse intrinsic pontine glioma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of diffuse intrinsic pontine glioma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with diffuse intrinsic pontine glioma across the seven major markets?
What is the size of the diffuse intrinsic pontine glioma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of diffuse intrinsic pontine glioma?
What will be the growth rate of patients across the seven major markets?
Diffuse Intrinsic Pontine Glioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for diffuse intrinsic pontine glioma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diffuse intrinsic pontine glioma market?
What are the key regulatory events related to the diffuse intrinsic pontine glioma market?
What is the structure of clinical trial landscape by status related to the diffuse intrinsic pontine glioma market?
What is the structure of clinical trial landscape by phase related to the diffuse intrinsic pontine glioma market?
What is the structure of clinical trial landscape by route of administration related to the diffuse intrinsic pontine glioma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DIFFUSE INTRINSIC PONTINE GLIOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DIFFUSE INTRINSIC PONTINE GLIOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DIFFUSE INTRINSIC PONTINE GLIOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 DIFFUSE INTRINSIC PONTINE GLIOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DIFFUSE INTRINSIC PONTINE GLIOMA - UNMET NEEDS
10 DIFFUSE INTRINSIC PONTINE GLIOMA - KEY ENDPOINTS OF TREATMENT
11 DIFFUSE INTRINSIC PONTINE GLIOMA - MARKETED PRODUCTS
11.1 List of Diffuse Intrinsic Pontine Glioma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 DIFFUSE INTRINSIC PONTINE GLIOMA - PIPELINE DRUGS
12.1 List of Diffuse Intrinsic Pontine Glioma Pipeline Drugs Across the Top 7 Markets
12.1.1 BXQ-350 - Bexion Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SONALA-001 - Sonalasense
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Unesbulin - PTC Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Fimepinostat - Curis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Indoximod - NewLink Genetics Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DIFFUSE INTRINSIC PONTINE GLIOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DIFFUSE INTRINSIC PONTINE GLIOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DIFFUSE INTRINSIC PONTINE GLIOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
16 DIFFUSE INTRINSIC PONTINE GLIOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DIFFUSE INTRINSIC PONTINE GLIOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DIFFUSE INTRINSIC PONTINE GLIOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DIFFUSE INTRINSIC PONTINE GLIOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DIFFUSE INTRINSIC PONTINE GLIOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DIFFUSE INTRINSIC PONTINE GLIOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 DIFFUSE INTRINSIC PONTINE GLIOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DIFFUSE INTRINSIC PONTINE GLIOMA - UNMET NEEDS
10 DIFFUSE INTRINSIC PONTINE GLIOMA - KEY ENDPOINTS OF TREATMENT
11 DIFFUSE INTRINSIC PONTINE GLIOMA - MARKETED PRODUCTS
11.1 List of Diffuse Intrinsic Pontine Glioma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 DIFFUSE INTRINSIC PONTINE GLIOMA - PIPELINE DRUGS
12.1 List of Diffuse Intrinsic Pontine Glioma Pipeline Drugs Across the Top 7 Markets
12.1.1 BXQ-350 - Bexion Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SONALA-001 - Sonalasense
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Unesbulin - PTC Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Fimepinostat - Curis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Indoximod - NewLink Genetics Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DIFFUSE INTRINSIC PONTINE GLIOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DIFFUSE INTRINSIC PONTINE GLIOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DIFFUSE INTRINSIC PONTINE GLIOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Diffuse Intrinsic Pontine Glioma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Diffuse Intrinsic Pontine Glioma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Diffuse Intrinsic Pontine Glioma - Access and Reimbursement Overview
16 DIFFUSE INTRINSIC PONTINE GLIOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DIFFUSE INTRINSIC PONTINE GLIOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DIFFUSE INTRINSIC PONTINE GLIOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
